Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

No detection of CD4-independent human immunodeficiency virus 1 envelope glycoproteins in brain tissue of patients with or without neurological complications.

Quitadamo B, Peters PJ, Koch M, Luzuriaga K, Cheng-Mayer C, Clapham PR, Gonzalez-Perez MP.

Arch Virol. 2019 Feb;164(2):473-482. doi: 10.1007/s00705-018-4094-1. Epub 2018 Nov 10.

2.

Ultradeep single-molecule real-time sequencing of HIV envelope reveals complete compartmentalization of highly macrophage-tropic R5 proviral variants in brain and CXCR4-using variants in immune and peripheral tissues.

Brese RL, Gonzalez-Perez MP, Koch M, O'Connell O, Luzuriaga K, Somasundaran M, Clapham PR, Dollar JJ, Nolan DJ, Rose R, Lamers SL.

J Neurovirol. 2018 Aug;24(4):439-453. doi: 10.1007/s13365-018-0633-5. Epub 2018 Apr 23.

PMID:
29687407
3.

HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.

Quitadamo B, Peters PJ, Repik A, O'Connell O, Mou Z, Koch M, Somasundaran M, Brody R, Luzuriaga K, Wallace A, Wang S, Lu S, McCauley S, Luban J, Duenas-Decamp M, Gonzalez-Perez MP, Clapham PR.

J Virol. 2018 Jan 2;92(2). pii: e00841-17. doi: 10.1128/JVI.00841-17. Print 2018 Jan 15.

4.

Identification of Emerging Macrophage-Tropic HIV-1 R5 Variants in Brain Tissue of AIDS Patients without Severe Neurological Complications.

Gonzalez-Perez MP, Peters PJ, O'Connell O, Silva N, Harbison C, Cummings Macri S, Kaliyaperumal S, Luzuriaga K, Clapham PR.

J Virol. 2017 Sep 27;91(20). pii: e00755-17. doi: 10.1128/JVI.00755-17. Print 2017 Oct 15.

5.

Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.

Beauparlant D, Rusert P, Magnus C, Kadelka C, Weber J, Uhr T, Zagordi O, Oberle C, Duenas-Decamp MJ, Clapham PR, Metzner KJ, Günthard HF, Trkola A.

PLoS Pathog. 2017 Mar 6;13(3):e1006255. doi: 10.1371/journal.ppat.1006255. eCollection 2017 Mar.

6.

Targeted Delivery of Glucan Particle Encapsulated Gallium Nanoparticles Inhibits HIV Growth in Human Macrophages.

Soto ER, O'Connell O, Dikengil F, Peters PJ, Clapham PR, Ostroff GR.

J Drug Deliv. 2016;2016:8520629. Epub 2016 Nov 14.

7.

Saturation Mutagenesis of the HIV-1 Envelope CD4 Binding Loop Reveals Residues Controlling Distinct Trimer Conformations.

Duenas-Decamp M, Jiang L, Bolon D, Clapham PR.

PLoS Pathog. 2016 Nov 7;12(11):e1005988. doi: 10.1371/journal.ppat.1005988. eCollection 2016 Nov.

8.

Infection of ectocervical tissue and universal targeting of T-cells mediated by primary non-macrophage-tropic and highly macrophage-tropic HIV-1 R5 envelopes.

Peters PJ, Gonzalez-Perez MP, Musich T, Moore Simas TA, Lin R, Morse AN, Shattock RJ, Derdeyn CA, Clapham PR.

Retrovirology. 2015 Jun 9;12:48. doi: 10.1186/s12977-015-0176-2.

9.

HIV-1 non-macrophage-tropic R5 envelope glycoproteins are not more tropic for entry into primary CD4+ T-cells than envelopes highly adapted for macrophages.

Musich T, O'Connell O, Gonzalez-Perez MP, Derdeyn CA, Peters PJ, Clapham PR.

Retrovirology. 2015 Mar 14;12:25. doi: 10.1186/s12977-015-0141-0.

10.

Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism.

O'Connell O, Repik A, Reeves JD, Gonzalez-Perez MP, Quitadamo B, Anton ED, Duenas-Decamp M, Peters P, Lin R, Zolla-Pazner S, Corti D, Wallace A, Wang S, Kong XP, Lu S, Clapham PR.

J Virol. 2013 Jan;87(1):187-98. doi: 10.1128/JVI.01834-12. Epub 2012 Oct 10.

11.

Independent evolution of macrophage-tropism and increased charge between HIV-1 R5 envelopes present in brain and immune tissue.

Gonzalez-Perez MP, O'Connell O, Lin R, Sullivan WM, Bell J, Simmonds P, Clapham PR.

Retrovirology. 2012 Mar 15;9:20. doi: 10.1186/1742-4690-9-20.

12.

The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies.

Dueñas-Decamp MJ, O'Connell OJ, Corti D, Zolla-Pazner S, Clapham PR.

Retrovirology. 2012 Jan 27;9:9. doi: 10.1186/1742-4690-9-9.

13.

Vaccinology: precisely tuned antibodies nab HIV.

Clapham PR, Lu S.

Nature. 2011 Sep 21;477(7365):416-7. doi: 10.1038/477416a. No abstract available.

PMID:
21938063
14.

Genotypic and functional properties of early infant HIV-1 envelopes.

Kishko M, Somasundaran M, Brewster F, Sullivan JL, Clapham PR, Luzuriaga K.

Retrovirology. 2011 Aug 15;8:67. doi: 10.1186/1742-4690-8-67.

15.

Stromal down-regulation of macrophage CD4/CCR5 expression and NF-κB activation mediates HIV-1 non-permissiveness in intestinal macrophages.

Shen R, Meng G, Ochsenbauer C, Clapham PR, Grams J, Novak L, Kappes JC, Smythies LE, Smith PD.

PLoS Pathog. 2011 May;7(5):e1002060. doi: 10.1371/journal.ppat.1002060. Epub 2011 May 26.

16.

Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors.

Brown RJ, Peters PJ, Caron C, Gonzalez-Perez MP, Stones L, Ankghuambom C, Pondei K, McClure CP, Alemnji G, Taylor S, Sharp PM, Clapham PR, Ball JK.

J Virol. 2011 Jun;85(12):6024-37. doi: 10.1128/JVI.00131-11. Epub 2011 Apr 6.

17.

A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection.

Musich T, Peters PJ, Duenas-Decamp MJ, Gonzalez-Perez MP, Robinson J, Zolla-Pazner S, Ball JK, Luzuriaga K, Clapham PR.

J Virol. 2011 Mar;85(5):2397-405. doi: 10.1128/JVI.02187-10. Epub 2010 Dec 15.

18.

Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis.

Duenas-Decamp MJ, Peters PJ, Repik A, Musich T, Gonzalez-Perez MP, Caron C, Brown R, Ball J, Clapham PR.

Future Virol. 2010 Jul;5(4):435-451.

19.

HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12.

Duenas-Decamp MJ, Clapham PR.

J Virol. 2010 Sep;84(18):9608-12. doi: 10.1128/JVI.00185-10. Epub 2010 Jul 7.

20.

Modulation of HIV-1 macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodies.

Richards KH, Aasa-Chapman MM, McKnight A, Clapham PR.

Retrovirology. 2010 May 27;7:48. doi: 10.1186/1742-4690-7-48.

21.

Complexity in human immunodeficiency virus type 1 (HIV-1) co-receptor usage: roles of CCR3 and CCR5 in HIV-1 infection of monocyte-derived macrophages and brain microglia.

Agrawal L, Maxwell CR, Peters PJ, Clapham PR, Liu SM, Mackay CR, Strayer DS.

J Gen Virol. 2009 Mar;90(Pt 3):710-22. doi: 10.1099/vir.0.006205-0.

PMID:
19218218
22.

Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection.

Shen R, Richter HE, Clements RH, Novak L, Huff K, Bimczok D, Sankaran-Walters S, Dandekar S, Clapham PR, Smythies LE, Smith PD.

J Virol. 2009 Apr;83(7):3258-67. doi: 10.1128/JVI.01796-08. Epub 2009 Jan 19.

23.

Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes.

Duenas-Decamp MJ, Peters PJ, Burton D, Clapham PR.

J Virol. 2009 Mar;83(6):2575-83. doi: 10.1128/JVI.02133-08. Epub 2009 Jan 7.

24.

Plugging gp120s cavity.

Repik A, Clapham PR.

Structure. 2008 Nov 12;16(11):1603-4. doi: 10.1016/j.str.2008.10.003.

25.

Human immunodeficiency viruses: propagation, quantification, and storage.

Richards KH, Clapham PR.

Curr Protoc Microbiol. 2006 Sep;Chapter 15:Unit15J.1. doi: 10.1002/9780471729259.mc15j01s02.

PMID:
18770581
26.

Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop.

Duenas-Decamp MJ, Peters P, Burton D, Clapham PR.

J Virol. 2008 Jun;82(12):5807-14. doi: 10.1128/JVI.02585-07. Epub 2008 Apr 2.

27.

Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.

Peters PJ, Duenas-Decamp MJ, Sullivan WM, Brown R, Ankghuambom C, Luzuriaga K, Robinson J, Burton DR, Bell J, Simmonds P, Ball J, Clapham PR.

Retrovirology. 2008 Jan 18;5:5. doi: 10.1186/1742-4690-5-5.

28.

Lack of alternative coreceptor use by pediatric HIV-1 R5 isolates for infection of primary cord or adult peripheral blood mononuclear cells.

Sullivan WM, Dorr P, Perros M, Hudson R, Leif J, Luzuriaga K, Clapham PR.

Arch Virol. 2008;153(2):363-6. Epub 2007 Dec 13.

PMID:
18074097
29.

Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues.

Peters PJ, Dueñas-Decamp MJ, Sullivan WM, Clapham PR.

J Neuroimmune Pharmacol. 2007 Mar;2(1):32-41. Epub 2006 Nov 7. Review.

PMID:
18040824
30.

Effects of vpu start-codon mutations on human immunodeficiency virus type 1 replication in macrophages.

Richards KH, Clapham PR.

J Gen Virol. 2007 Oct;88(Pt 10):2780-92.

PMID:
17872532
31.

The promise of CCR5 antagonists as new therapies for HIV-1.

Repik A, Richards KH, Clapham PR.

Curr Opin Investig Drugs. 2007 Feb;8(2):130-9. Review.

PMID:
17328229
32.

Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.

Gorry PR, Dunfee RL, Mefford ME, Kunstman K, Morgan T, Moore JP, Mascola JR, Agopian K, Holm GH, Mehle A, Taylor J, Farzan M, Wang H, Ellery P, Willey SJ, Clapham PR, Wolinsky SM, Crowe SM, Gabuzda D.

Virology. 2007 May 25;362(1):163-78. Epub 2007 Jan 18.

33.

Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis.

Peters PJ, Sullivan WM, Duenas-Decamp MJ, Bhattacharya J, Ankghuambom C, Brown R, Luzuriaga K, Bell J, Simmonds P, Ball J, Clapham PR.

J Virol. 2006 Jul;80(13):6324-32.

34.
35.
36.
39.

CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo.

Bhattacharya J, Peters PJ, Clapham PR.

AIDS. 2003;17 Suppl 4:S35-43. Review. No abstract available.

PMID:
15080178
40.
41.

CD4-dependent and CD4-independent HIV-2: consequences for neutralization.

Thomas ER, Shotton C, Weiss RA, Clapham PR, McKnight A.

AIDS. 2003 Feb 14;17(3):291-300.

PMID:
12556682
42.

Cell surface receptors, virus entry and tropism of primate lentiviruses.

Clapham PR, McKnight A.

J Gen Virol. 2002 Aug;83(Pt 8):1809-29. Review.

PMID:
12124446
43.

HIV-1 receptors and cell tropism.

Clapham PR, McKnight A.

Br Med Bull. 2001;58:43-59. Review.

PMID:
11714623
44.

A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors.

Blanpain C, Buser R, Power CA, Edgerton M, Buchanan C, Mack M, Simmons G, Clapham PR, Parmentier M, Proudfoot AE.

J Leukoc Biol. 2001 Jun;69(6):977-85.

PMID:
11404385
45.

Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands.

Simmons G, Reeves JD, Hibbitts S, Stine JT, Gray PW, Proudfoot AE, Clapham PR.

Immunol Rev. 2000 Oct;177:112-26. Review.

PMID:
11138769
46.

The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity.

Proudfoot AE, Fritchley S, Borlat F, Shaw JP, Vilbois F, Zwahlen C, Trkola A, Marchant D, Clapham PR, Wells TN.

J Biol Chem. 2001 Apr 6;276(14):10620-6. Epub 2000 Dec 14.

47.
48.

A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry.

Sabroe I, Peck MJ, Van Keulen BJ, Jorritsma A, Simmons G, Clapham PR, Williams TJ, Pease JE.

J Biol Chem. 2000 Aug 25;275(34):25985-92.

49.

Differential activation of CC chemokine receptors by AOP-RANTES.

Elsner J, Mack M, Brühl H, Dulkys Y, Kimmig D, Simmons G, Clapham PR, Schlöndorff D, Kapp A, Wells TN, Proudfoot AE.

J Biol Chem. 2000 Mar 17;275(11):7787-94.

50.

Coreceptor ligand inhibition of fetal brain cell infection by HIV type 1.

Hibbitts S, Reeves JD, Simmons G, Gray PW, Epstein LG, Schols D, de Clercq E, Wells TN, Proudfoot AE, Clapham PR.

AIDS Res Hum Retroviruses. 1999 Jul 20;15(11):989-1000.

PMID:
10445811

Supplemental Content

Loading ...
Support Center